School of Medicine
Showing 1-21 of 21 Results
-
Oliver O. Aalami, MD
Clinical Professor, Surgery - Vascular Surgery
Current Research and Scholarly InterestsWe launched a national precision medicine PAD trial called, VascTrac (http://vasctrac.stanford.edu/). This trial is mobile phone based and leverages Apple's ResearchKit Platform to monitor a patient's activity both pre- and post-intervention. We are validating mobile phone surveillance for PAD patients and are currently enrolling.
-
Oscar J. Abilez
Senior Scientist, Cardiothoracic Surgery - Pediatric Cardiac Surgery
Current Research and Scholarly InterestsDr. Abilez' interests are aimed at elucidating how various biophysical and biochemical perturbations regulate early cardiovascular development across time and length scales that span several orders of magnitude, using human pluripotent stem cells as a model system.
-
Kevin M. Alexander, MD, FACC, FHFSA
Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
BioDr. Alexander is an advanced heart failure-trained cardiologist. He is also an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine.
Dr. Alexander specializes in the management of advanced heart failure and transplant cases, seeing a wide range of patients. He also has an active research laboratory, studying various forms of heart failure.
Dr. Alexander has expertise in diagnosing and treating transthyretin cardiac amyloidosis, a critical yet underdiagnosed cause of heart failure among African Americans and the elderly. He is conducting extensive research to enhance our understanding of this condition, with grant support from the National Institutes of Health and American Heart Association, among other sources. -
Russ B. Altman
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine, of Biomedical Data Science, Senior Fellow at the Stanford Institute for HAI and Professor, by courtesy, of Computer Science
Current Research and Scholarly InterestsI refer you to my web page for detailed list of interests, projects and publications. In addition to pressing the link here, you can search "Russ Altman" on http://www.google.com/
-
Cristina Maria Alvira
Associate Professor of Pediatrics (Critical Care)
On Leave from 04/01/2024 To 08/01/2024Current Research and Scholarly InterestsThe overall objective of the Alvira Laboratory is to elucidate the mechanisms that promote postnatal lung development and repair, by focusing on three main scientific goals: (i) identification of the signaling pathways that direct the transition between the saccular and alveolar stages of lung development; (ii) exploration of the interplay between postnatal vascular and alveolar development; and (iii) determination of developmentally regulated pathways that mediate lung repair after injury.
-
Katrin Andreasson
Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences
Current Research and Scholarly InterestsOur research focuses on understanding how immune responses initiate and accelerate synaptic and neuronal injury in age-related neurodegeneration, including models of Alzheimer's disease and Parkinson's disease. We also focus on the role of immune responses in aggravating brain injury in models of stroke. Our goal is the identification of critical immune pathways that function in neurologic disorders and that can be targeted to elicit disease modifying effects.
-
Lay Teng Ang
Instructor, Institute for Stem Cell Biology and Regenerative Medicine
BioAs a stem cell biologist, I aim to understand the mechanisms through which stem cells differentiate into progressively specialized cell types and to harness this knowledge to artificially generate pure populations of desired cell types from stem cells. My work over the past ten years has centered on pluripotent stem cells (PSCs, which include embryonic and pluripotent stem cells), which can generate any of the hundreds of diverse cell types in the body. However, it has been notoriously challenging to guide PSCs to differentiate into a pure population of a given cell type. Current differentiation strategies typically generate heterogeneous cell populations unsuitable for basic research or clinical applications. To address this challenge, I mapped the cascade of branching lineage choices through which PSCs differentiate into various endodermal and mesodermal cell types. I then developed effective methods to differentiate PSCs into specific lineages by providing the extracellular signal(s) that specify a given lineage while inhibiting the signals that induce the alternate fate(s), enabling the generation of highly-pure human heart and bone (Loh & Chen et al., 2016; Cell) and liver (Loh & Ang et al., 2014; Cell Stem Cell) from PSCs. My laboratory currently focuses on differentiating human PSCs into liver progenitors (Ang et al., 2018; Cell Reports) and blood vessel cells (Ang et al., 2022; Cell).
I earned my Ph.D. jointly from the University of Cambridge and A*STAR and was subsequently appointed as a Research Fellow and, later, a Senior Research Fellow at the Genome Institute of Singapore. I then moved my laboratory to Stanford University as a Siebel Investigator and Instructor at the Stanford Institute for Stem Cell Biology & Regenerative Medicine. My laboratory has been supported by the Siebel Investigatorship, California Institute for Regenerative Medicine, and other sources. -
Timothy Angelotti MD, PhD
Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly InterestsMy research efforts are focused on investigating the pharmacological and physiological interface of the autonomic nervous system with effector organs. Utilizing molecular, cellular, and electrophysiological techniques, we are examining alpha2 adrenergic receptor function in cultured sympathetic neurons. Future research aims will be directed toward understanding neurotransmitter release in general.
-
Martin S. Angst
Professor of Anesthesiology, Perioperative and Pain Medicine
On Partial Leave from 03/21/2024 To 04/19/2024Current Research and Scholarly InterestsOur laboratory studies biological and clinical determinants of human resilience using surgery as an injury model.
-
Justin P. Annes M.D., Ph.D.
Associate Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
DIABETES
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families. -
Eric Appel
Associate Professor of Materials Science and Engineering, Senior Fellow at the Woods Institute for the Environment and Associate Professor, by courtesy, of Pediatrics (Endocrinology)
Current Research and Scholarly InterestsThe underlying theme of the Appel Lab at Stanford University integrates concepts and approaches from supramolecular chemistry, natural/synthetic materials, and biology. We aim to develop supramolecular biomaterials that exploit a diverse design toolbox and take advantage of the beautiful synergism between physical properties, aesthetics, and low energy consumption typical of natural systems. Our vision is to use these materials to solve fundamental biological questions and to engineer advanced healthcare solutions.
-
Amin Arbabian
Associate Professor of Electrical Engineering
Current Research and Scholarly InterestsMy group's research covers RF circuits and system design for (1) biomedical, (2) sensing, and (3) Internet of Things (IoT) applications.
-
Shipra Arya
Professor of Surgery (Vascular Surgery)
BioShipra Arya, MD SM FACS is a Professor of Surgery at the Stanford University School of Medicine and section chief of vascular surgery at VA Palo Alto Healthcare System. She has a Master’s degree in epidemiology from the Harvard School of Public Health with focus on research methodology and cardiovascular epidemiology. She completed her General Surgery Residency at Creighton University Medical Center followed by a Vascular Surgery Fellowship at University of Michigan. She has been funded by American Heart Association (AHA), NIH/NIA GEMSSTAR grant, VA Palo Alto Center for Innovation and Implementation (Ci2i), and is currently funded by VA HSR&D for a multicenter stepped wedge cluster randomized clinical trial called “PAtient-centered mUltidiSciplinary Care for vEterans Undergoing Surgery (PAUSE) trial”. Her current work focuses on streamlining frailty evaluation, as well as implementation of patient and system level interventions to improve surgical quality and to provide high-value and patient centered care.
She has multiple administrative roles in surgical quality improvement as Director of Surgical Quality at VAPAHCS; Center director for Stanford University in the Vascular Quality Initiative (VQI); and the Associate Medical Director of the Northern California region for VQI, which is the national registry database and patient safety organization for Society for Vascular Surgery (SVS). Her involvement in SVS VQI also extends to being a member of the steering committee of the Vascular Implant Surveillance and Interventional Outcomes Network (VISION) to improve the quality, safety and effectiveness of vascular care. She also serves as the President of the Surgical Outcomes Club, a national organization of surgical health services researchers, and chairs multiple national committees: VA surgeons committee for the SVS and Diversity and Inclusion Committee for the Association of VA surgeons. -
Euan A. Ashley
Associate Dean, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Current Research and Scholarly InterestsThe Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.
-
Ritu Asija
Clinical Professor, Pediatrics - Cardiology
BioI specialize in providing cardiac critical care to infants, children and adults with congenital heart disease and heart failure. I am the Associate Director for the Pulmonary Artery Reconstruction Program at Stanford, helping to coordinate comprehensive multidisciplinary care for children with severe pulmonary artery abnormalities and right ventricular dysfunction. I was a Faculty Fellow at the Stanford Center for Biodesign in 2019-2020 and continue to work on development of new technologies for the unmet needs of pediatric patients. I have an interest in physician wellness and completed the Wellness Director course through the WellMD Center at Stanford.
-
Themistocles (Tim) Assimes
Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsGenetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes
-
Jennifer Avise, MD
Member, Cardiovascular Institute
BioDr. Avise is a board-certified vascular surgeon specializing in cutting edge treatments of vascular disease. She is a clinical assistant professor in the Department Surgery, Division of Vascular Surgery at Stanford University School of Medicine.
She has helped to expand access to expert vascular surgery in the East Bay, establishing Stanford Health Care’s first vascular surgery practices at the medical center in Emeryville and at the Stanford Health Care – ValleyCare hospital in Pleasanton. Dr. Avise serves as the medical director of the Pleasanton vascular laboratory, an IAC accredited facility, where she advances developments in noninvasive testing to aid in early diagnosis of vascular disease.
Her focus is on early detection and disease prevention, minimally invasive (endovascular) techniques, and complex open surgery. She treats a wide variety of conditions, including aortic aneurysm, limb salvage, varicose veins, peripheral vascular disease, carotid disease, complex wound care, and dialysis access. -
David M. Axelrod, MD
Clinical Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsVirtual Reality Congenital Heart Disease experience: The Stanford Virtual Heart. Currently engaged with 19 academic medical centers across the globe using our Stanford Virtual Heart to educate students and trainees, and research our VR experience as a means for training and education. Also developing next generation modeling and image interaction with Stanford engineers and educators, to promote personalized surgical training in VR and advanced educational programs in congenital heart disease.
-
Dan E. Azagury, MD, FACS
Associate Professor of Surgery (General Surgery)
Current Research and Scholarly Interests.
